Articles related to IMMUNOTHERAPY

Recent trials in NSCLC treatment reveal that perioperative immunotherapy, including combinations like nivolumab and chemotherapy, can significantly improve disease-free survival in early-stage resectable NSCLC.

In the CheckMate 77T trial, perioperative nivolumab plus chemotherapy followed by adjuvant nivolumab significantly improved event-free survival and pathological responses in patients with resectable NSCLC. The safety profile was consistent with known data, reinforcing nivolumab’s potential as a cornerstone in perioperative lung cancer therapy.

In a challenging case of polyarteritis nodosa, angiography and histopathology provided crucial diagnostic insights, leading to successful management through tailored immunosuppressive therapy.

This phase 2 study underscores the challenges in enhancing therapeutic outcomes in metastatic castration-resistant prostate cancer with AZD4635 combined with immunotherapy, indicating a minimal PSA response among treated patients.

In the recent KEYNOTE-564 trial, adjuvant pembrolizumab therapy was shown to increase the 48-month overall survival rate to 91.2% compared to 86.0% with placebo among post-surgical patients with renal-cell carcinoma at increased risk of recurrence.

In this study, dostarlimab combined with carboplatin-paclitaxel demonstrated a marked improvement in progression-free and overall survival among endometrial cancer patients, particularly those with genetic markers for dMMR and MSI-H.